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José M. Bellón2,3, pablo Ryan4 & salvador Resino  1
the dried blood spot (DBs) is increasingly used for the hepatitis C virus (HCV) screening. our objective 
was to perform a meta-analysis of the methodology for HCV screening in DBs samples, particularly in 
the type of diagnostic assay used. We performed a meta-analysis of all eligible studies published to date 
(March 2018). The literature search revealed 26 studies: 21 for detection of anti-HCV antibodies and 10 
for detection of HCV-RNA. statistical analyses were performed using Meta-Disc and stAtA (MIDAs 
module). For detection of HCV antibodies, pooled diagnostic accuracy measures were as follows: 
sensitivity 96.1%, specificity 99.2%, positive likelihood ratio (PLR) 105, negative likelihood ratio (NLR) 
0.04, diagnostic odds ratio (DOR) 2692.9, and summary receiver operating characteristic (SROC) 
0.997 ± 0.001. For detection of HCV-RNA, the pooled diagnostic accuracy measures were as follows: 
sensitivity 97.8%, specificity 99.2%, PLR 44.8, NLR 0.04, DOR 1966.9, and SROC 0.996 ± 0.013. Similar 
values of pooled diagnostic accuracy measures were found according to the type of anti-HCV antibody 
detection assay (enzyme-linked immunosorbent assay, rapid diagnostic test, and chemiluminescence 
assays) and HCV-RNA detection assay (real-time polymerase chain reaction and transcription-mediated 
amplification). The analysis of external validity showed a high negative predicted value (NPV) for both 
approaches, but a low positive predicted value (ppV) when prevalence was < 10%, particularly in HCV-
RNA tests. Finally, this meta-analysis is subject to limitations, especially publication bias and significant 
heterogeneity between studies. In conclusion, HCV screening in DBs samples has an outstanding 
diagnostic performance, with no relevant differences between the techniques used. However, external 
validity may be limited when the HCV prevalence is low.
About 71 million people have chronic Hepatitis C virus (HCV) infection and around 80% are undiagnosed1, 
thus leading to the development of liver disease and/or transmission of HCV infection to others unknowingly2–4. 
Furthermore, HCV diagnosis remains problematic for persons from low- and middle -income countries (LMICs) 
and difficult-to-access populations in developed countries (people who inject drugs [PWID], homeless people, 
immigrants, and sex workers), where very few individuals have access to diagnosis2,5,6.
The standard HCV diagnosis requires an initial serological test, followed by a confirmatory nucleic acid 
test (NAT) for the detection of HCV ribonucleic acid (RNA) in serum/plasma samples obtained during rou-
tine venous blood collection4,6,7. The tests require high-cost facilities and equipment (not always available in 
resource-limited settings) and specialized personnel and adequate infrastructures for the collection, transport, 
and storage of venous blood samples6. In addition, some patients, such as PWIDs, may have limited venous 
access, which further hampers diagnosis2.
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Several strategies have been proposed to overcome some of these limitations2,5,8. One is the use of dried 
blood spots (DBS), which are obtained by finger puncture and depositing the blood drops on a filter paper. Such 
an approach can be used for HCV diagnosis in serological tests (anti-HCV antibodies) and in virological tests 
(HCV-RNA)9. DBS facilitates the sampling process by avoiding venipuncture and removing the need to separate 
plasma samples. In addition, DBS samples are highly stable at room temperature, and it is not necessary to main-
tain the cold chain for the storage of the samples and transport to the processing laboratory10. These advantages 
have made DBS sampling a promising approach to HCV screening and epidemiological surveillance in LMICs 
and risk groups11–14.
DBS is increasingly used for HCV screening, although the sensitivity and specificity of this approach for 
hepatitis C remain uncertain. Additionally, the laboratory methodology used for the analysis of DBS samples is 
very diverse, covering a wide range of settings15–17. In recent years, several systematic reviews and meta-analyses 
on this topic have been published15–19. However, to our knowledge, none has performed a detailed analysis of the 
diagnostic accuracy of laboratory-based screening for HCV. Therefore, our aim was to carefully analyze the diag-
nostic performance of the methodology that enables the detection of HCV infection in DBS samples, particularly 
in the type of diagnostic assay used, by conducting a meta-analysis of all eligible studies published to date (March 
2018).
Material and Methods
The meta-analysis was conducted following guidelines on systematic reviews and meta-analyses (PRISMA; see 
Supplemental File (SF) 1)20.
search strategy. Relevant studies were identified by a literature search in PubMed, Scopus, Embase, Lilacs, 
Web of Science, and the Cochrane Library with the following terms: (“hepatitis C” OR HCV) AND (DBS OR 
Whatman OR “filter paper” OR “Dried blood spot” OR “Dried blood filter” OR “Dried blood” OR “Dried sam-
ple”) AND (sensitivity OR specificity OR “Positive Predictive Value” OR “Negative Predictive Value” OR AUROC 
OR AUCROC OR diagnostic OR screening) NOT (review). We also reviewed the reference lists of several previ-
ously published reviews on HCV screening in DBS. The information contained in this report is based on articles 
published before March 2018.
study selection. The inclusion and exclusion criteria were established before proceeding to the search and 
review. The inclusion criteria were as follows: (1) studies had to have evaluated the detection of anti-HCV anti-
bodies and/or HCV-RNA in DBS; (2) results for DBS had to have been compared with a reference method (gold 
standard) using serum, plasma, or whole blood samples; (3) there had to be enough available data to construct 
2 × 2 tables and to calculate the number of true positives (TP), true negatives (TN), false positives (FP), and 
false negatives (FN). The articles excluded were as follows: (1) studies whose objective differed from that of the 
meta-analysis; (2) editorial comments, reviews, opinion letters, and conference proceedings; (3) studies with 
insufficient data to estimate the sensitivity and/or specificity of the techniques evaluated; and (4) studies in which 
all samples were not tested using at least a reference test or in which a reference test was performed only on a 
subset of samples (only positive, negative, or discordant results).
We based our selection of eligible articles on careful screening of the title and abstract; when an article fulfilled 
the inclusion criteria, the full text was examined, and data were extracted. Moreover, when a study included 
different subgroups with various diagnostic tests, only those subgroups that met the inclusion criteria were 
included in our meta-analysis. In the case of antibody detection assays, if a receiver operating characteristic 
(ROC) curve analysis was performed to determine the optimal cut-off point, we only included the data obtained 
with the cut-off point established by the manufacturer for the use of serum or plasma samples. However, some 
investigators also determined others cut-off points based on ROC curve analysis, which were excluded from the 
meta-analysis.
Data extraction. Data were extracted independently by 2 investigators (B.A. and S.V.M.) and then 
cross-checked. When data were unclear or required assumptions to be made, other investigators (S.R. and 
M.A.J.S.) were consulted to reach a consensus. The values of TP, TN, FP, and FN corresponding to the tests 
evaluated in each article were extracted in order to create 2×2 contingency tables and calculate sensitivity and 
specificity. When this information was not explicitly reported, we contacted the corresponding author to request 
the data. If we did not receive the necessary data, the study was excluded.
Quality assessment. Study quality and risk of bias were evaluated using QUADAS-2 (Quality Assessment of 
Diagnostic Accuracy studies 2)21, which is designed to evaluate the quality of primary diagnostic accuracy studies 
through 4 key domains (patient selection, index test, reference standard, and flow and timing). Each domain was 
assessed in terms of risk of bias (low, high, or unclear) and, in the first 3 domains, concerns about applicability 
(low, high, or unclear) were also considered. Two reviewers (B.A. and S.V.M.) independently assessed the study 
characteristics and methodological quality.
statistical analysis. Data were analyzed using Meta-DiSc 1.422 and STATA (version 14, STATA Corp., Texas 
USA) with the MIDAS module. Analyses were performed according to the HCV detection method. First, we 
performed the analysis of HCV-antibody detection studies and HCV-RNA detection studies separately. Next, we 
performed a subgroup analysis within each of the above categories: anti-HCV antibody detection (enzyme-linked 
immunosorbent assay [ELISA], rapid diagnostic tests (RDTs), and chemiluminescence assays [CLA]) and 
HCV-RNA detection (real-time polymerase chain reaction [PCR] and transcription-mediated amplification 
[TMA]). Analyses were performed only when 3 or more articles were available.
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We calculated the pooled estimates of sensitivity, specificity, positive predicted value (PPV), negative predicted 
value (NPV), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and 
their corresponding 95% confidence intervals (95%CI) using the accuracy data (TP, FP, FN, and TN) extracted 
from each eligible study. We used a random effects model (DerSimonian-Laird method), since there was sig-
nificant between-study variability23. In order to facilitate analysis, a value of 0.5 was added to those cells that 
contained the value zero.
The data were displayed graphically on forest-plots, summary ROC (SROC) curves, and likelihood ratio scat-
ter plots. Heterogeneity was measured using the Cochran’s Q test and the inconsistency index (I2). The Cochran’s 
Q was calculated as the weighted sum of squared differences between individual study effects and the pooled 
effect across studies and P-values were calculated by comparing the statistic with a χ2 distribution with k-1 
degrees of freedom (where k is the number of studies). The I² statistic describes the percentage of total variation 
across studies due to heterogeneity rather than sampling error (chance). A p-value ≤ 0.05 and an I2 value ≥ 50% 
indicated significant heterogeneity. Sensitivity analyses were performed by sequential omission of individual 
outlier studies to investigate the influence of each study on the pooled estimates. In addition, we performed a 
meta-regression analysis for anti-HCV antibody detection assays and HCV-RNA detection assays with the aim of 
defining the potential effect of different covariates on diagnostic accuracy measures. For this purpose, we used the 
restricted maximum likelihood method and weighted least-squares model, with weights obtained from the study 
sizes. The covariates analyzed were as follows: study performed after 2010, study performed in LMICs, HIV coin-
fection, type of HCV detection test, capillary or venous DBS samples, and anti-HCV or HCV-RNA prevalence. 
A statistically significant linear relationship was one with a p-value ≤ 0.05. Publication bias was assessed using 
Deek’s funnel plot, and a P value < 0.05 indicated the presence of publication bias.
Results
search results. The literature search yielded 136 articles (Fig. 1A), of which 110 were excluded because they 
did not meet the inclusion criteria or presented an exclusion criterion. The remaining 26 eligible studies com-
prised 21 that were selected for the anti-HCV antibody detection meta-analysis9,24–43 and 10 for the HCV-RNA 
detection meta-analysis9,24,27,38,39,44–48. Five studies were included in both analyses9,24,27,38,39.
Article characteristics. The main characteristics of the articles are summarized in Table 1 for the anti-HCV 
antibody detection meta-analysis and Table 2 for the HCV-RNA detection meta-analysis. The publication year 
of the studies ranged from 2002 to 2018. A total of 9679 DBS samples from 9679 individuals were included for 
anti-HCV antibody detection, and 2201 DBS samples from 2015 individuals were included for HCV-RNA detec-
tion. The median prevalence was 51.1% for anti-HCV antibodies (p25th = 24.3%; p75th = 64.3%) and 61.8% 
for HCV-RNA (p25th = 60.5%; p75th = 70.1%). Eleven studies provided information about HCV genotypes in 
infected individuals9,24,32,36,37,40,41,45–48. Only 7 studies included the HIV/HCV coinfection status24,28,29,31,37,38,47. 
Most of the studies (n = 15) were based on DBS samples obtained by spotting whole venous blood on filter paper, 
12 were based on capillary DBS samples24,25,27,29,31,33,37,38,41–43,49, 2 on DBS samples obtained by either capillary or 
venous blood33,41, and 1 on mock DBS made by diluting the Second WHO International Standard for HCV-RNA 
in negative blood46.
Quality was assessed using QUADAS-2 (Fig. 1 and SF 2). Quality scores are summarized in Fig. 1B1 for the 
anti-HCV antibody detection assays and Fig. 1B2 for the HCV-RNA detection assays. The overall quality of the 
studies was moderate and most did not use a random or consecutive sampling method. Additionally, a signifi-
cant percentage of studies did not hide the results of the reference test or did not report blinding of laboratory 
personnel to the results of the reference test. As for concerns about the applicability of the studies, the risk of bias 
was low in all cases.
Figure 1. Summary of study selection process (A) and quality assessment using the QUADAS-2 tool (B): (B1) 
Results of quality assessment of anti-HCV antibody detection studies; (B2) Results of quality assessment of 
HCV-RNA detection studies. Abbreviations: HCV, hepatitis C virus; RNA, ribonucleic acid; QUADAS, quality 
assessment of diagnostic accuracy studies.
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Meta-analysis of anti-HCV antibody detection in DBs samples. A total of 30 anti-HCV antibodies 
assays from 21 different studies were analyzed: 22 ELISA9,24–37,41–43, 5 RDT31,40, and 3 CLA36,38,39. Publication bias 
was detected using Deek’s funnel plot asymmetry test (P = 0.001) (SF 3).
Pooled diagnostic accuracy measures are shown in Fig. 2. Sensitivity was 96.1% (95%CI = 95.4%; 96.7%), 
specificity 99.2% (95%CI = 99.0%; 99.4%), PLR 105.0 (95%CI = 53.8; 204.6), NLR 0.04 (95%CI = 0.03; 0.07), 



















2013 Brandao et al.25 — No Brazil 40 43.8 Monolisa HCV AgAb ULTRA Assay (Bio-Rad)
Monolisa HCV AgAb ULTRA Assay 
(Bio-Rad) 386 40 95 100
2013 Brandao et al.25 — No Brazil 40 43.8 Murex HCV AgAb combination EIA (Diasorin)
Murex HCV AgAb combination EIA 
(DiaSorin) 386 40 82.5 98
2006 Croom et al.26 — No Australia — — Monolisa anti-HCV PLUS Version 2 EIA (Bio-Rad)
Monolisa anti-HCV PLUS Version 2 
EIA (Bio-Rad) 183 75 100 100
2014 Dokubo el al27 — No USA  < 30 — ELISA HCV Version 3.0 (Ortho-Clinical Diagnostics)
Third-generation ELISA or CLA 
(Unspecified) 148 77 70.1 100
2017 Flores et al.28 — Yes Brazil 50.9 52 Murex anti-HCV (DiaSorin) Murex anti-HCV (DiaSorin) 524 278 92.1 99.2
2003 Judd et al.29 — Yes UK — — HCV 3.0 SAVe ELISA (Ortho-Clinical Diagnostics)
HCV 3.0 SAVe ELISA (Ortho-Clinical 
Diagnostics) 633 252 99.2 100
2013 Kania et al.30 — No Burkina Faso 29.8 37.2
Monolisa HCV Ab-Ag ULTRA Assay 
(Bio-Rad)
Monolisa HCV Ab-Ag ULTRA Assay 
(Bio-Rad) 218 5 100 100
2012 Larrat et al.31 — Yes France 46.5 61.9 Monolisa HCV Ab-Ag ULTRA Assay (Bio-Rad)
Monolisa HCV Ab-Ag ULTRA Assay 
(Bio-Rad) 201 113 98.2 100
2013 Lima41 — No Brazil 38.5 39.8 Murex anti-HCV v.4.0, (DiaSorin) Murex anti-HCV v.4.0 (DiaSorin) 1043 7 57.1 100
2013 Lima41 — No Brazil 38.5 39.8 Murex anti-HCV v.4.0, (DiaSorin) Murex anti-HCV v.4.0 (DiaSorin) 491 5 40.0 99.8
2013 Lima41 — No Brazil 38.5 39.8 Murex anti-HCV v.4.0, (DiaSorin) Murex anti-HCV v.4.0 (DiaSorin) 254 228 91.7 92.3
2016 Marques et al.32 1b, 1a, 3 No Brazil 47.3 43.5 HCV Ab (RADIM diagnostic) HCV Ab (RADIM diagnostic) 99 59 94.9 100
2012 Marques et al.33 — No Brazil 40 43.8 HCV Ab (RADIM diagnostic) HCV Ab (RADIM diagnostic) 411 40 97.5 99.5
2012 Marques et al.33 No Brazil 40 43.8 ETI-AB-HCVK-4 (DiaSorin) ETI-AB-HCVK-4 (DiaSorin) 411 45 88.9 96.1
1999 McCarron  et al.34 — No UK Monolisa anti-HCV (Sanofi Pasteur)
AxSYM HCV version 3.0 (Abbott 
Diagnostics) 220 108 100 87.5
2014 Nandagopal et al.35 — No India — — Anti-HCV ELISA (Murex Biotech S.A) Anti-HCV ELISA (Murex Biotech S.A) 60 31 100 100
2001 O’Brien42 No USA 44.8 38 Third-generation EIA in DBS Third-generation EIA in blood 1090 404 98.3 100
2012 Rice et al.43 — No UK — — Chiron V3.0 SaVE assay (Ortho-Clinical Diagnostics) Unspecified 93 59 98.3 100
2016 Soulier et al.9 1, 2, 3, 4, 5a, 6 No France 54 55.2
aHCV VITROS ECi (Ortho-Clinical 
Diagnostics)
aHCV VITROS ECi (Ortho-Clinical 
Diagnostics) 511 341 99.1 98.2
2015 Tejada-Strop et al.36
1a, 1c, 
2, 3 No USA — —
HCV 3.0 EIA (Ortho-Clinical 
Diagnostics)
HCV 3.0 EIA (Ortho-Clinical 
Diagnostics) 103 52 90 100
2010 Tuaillon et al.37 1, 2, 3, 4 Yes France — — HCV 3.0 EIA (Ortho-Clinical Diagnostics)
HCV 3.0 EIA (Ortho-Clinical 
Diagnostics) 200 100 99 98
2018 Vázquez-Morón et al.24
1a, 1b, 2, 
3, 4, 5 Yes Spain 44.3 66.9 Murex anti-HCV kit, v.4.0 (DiaSorin,) ADVIA Centaur® HCV assay 139 108 92.6 100
Chemiluminescence immunoassays
2016 Mössner et al.38 — Yes Denmark — — Architect anti-HCV assay (Abbott Diagnostics)
Architect anti-HCV assay (Abbott 
Diagnostics) 404 116 96.6 100
2013 Ross et al.39 — No Germany — — Architect anti-HCV assay (Abbott Diagnostics)
Architect anti-HCV assay (Abbott 
Diagnostics) 339 179 97.8 100
2015 Tejada-Strop et al.36
1a, 1c, 
2, 3 No USA — —
VITROS anti-HCV IgG CLA (Ortho-
Clinical Diagnostics)
VITROS anti-HCV IgG CLA (Ortho-
Clinical Diagnostics) 103 52 92 100
Rapid diagnostic tests
2012 Larrat et al.31 — Yes France 46.5 61.9 OraQuick HCV Rapid Antibody Test (OraSure Technologies)
Monolisa HCV AbAg ULTRA Assay 
(Bio-Rad) 201 113 97.4 100
2016 Poiteau et al.40 1a, 1b, 2, 3a, 4, 6 No France — —
OraQuick HCV Rapid Antibody Test 
(OraSure Technologies)
aHCV VITROS ECi (Ortho-Clinical 
Diagnostics 207 139 100 100
2016 Poiteau et al.40 1a, 1b, 2, 3a, 4, 6 No France — —
First Response® HCV Card Test (Premier Medical Corporation Ltd)
aHCV VITROS ECi (Ortho-Clinical 
Diagnostics 207 139 99.3 100
2016 Poiteau et al.40 1a, 1b, 2, 3a, 4, 6 No France — —
Assure HCV Rapid Test (MP 
Diagnostics)
aHCV VITROS ECi (Ortho-Clinical 
Diagnostics 207 139 98.6 100
2016 Poiteau et al.40 1a, 1b, 2, 3a, 4, 6 No France — —
MultiSure HCV Antibody Assay (MP 
Diagnostics)
aHCV VITROS ECi (Ortho-Clinical 
Diagnostics) 207 139 98.6 100
Table 1. Characteristics of the Studies Included in Meta-Analysis for Antibody Detection. Abbreviations: 
Ab, antibody; Ag, antigen; Anti-HCV, HCV antibodies; CLA, chemiluminescence assay; DBD, dried blood 
spot; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; GT, genotype; HCV, hepatitis 
C virus; HIV, human immunodeficiency virus; Se, sensitivity; Sp, specificity; TMA, transcription mediated 
amplification.
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statistical measures showed values of I2 > 50% (P < 0.05), suggesting substantial heterogeneity. However, accord-
ing to the sensitivity analysis, no individual study had a significant influence on pooled estimates. The likelihood 
scatter-plot (Fig. 3A1) shows a matrix of values of PLR and NLR. Most studies were in the left upper quadrant 
(LUQ), which means that anti-HCV antibody detection tests from DBS samples are useful for confirmation and 
exclusion of exposure to HCV. We also calculated the theoretical values of PPV and NPV using pooled values of 
PLR (105.0) and NLR (0.04) and plotted them against increasing anti-HCV antibody prevalence (Fig. 3B1, full 
description in SF 4). We found a PPV of 84.7% for a 5% prevalence and 92.1% for a 10% prevalence, whereas NPV 
continued with values above 93% when prevalence reached 60%.
We also performed an analysis according to the type of anti-HCV antibody detection assay: ELISA (SF 5), 
RDT (SF 1), and CLA (SF 7). Diagnostic accuracy measures were similar for ELISA, RDT, and CLA, and in turn 
similar to the global estimates for anti-HCV antibody detection (Fig. 2). For ELISA, PPV was 82.5% for a 5% 
prevalence and 90.8% for a 10% prevalence; for RDT, PPV was 88.3% for a 5% prevalence and 94.1% for a 10% 
prevalence; and for CLA, PPV was 93.1% for a 5% prevalence and 96.6% for a 10% prevalence, whereas NPV 
was ≥ 91% for ELISA, RDT, and CLA when prevalence reached 60% (SF 4).
Meta-regression results are shown in SF 7. In the univariate analysis, we found significant values for studies 
performed after 2010 (p = 0.041) and in LMICs (p < 0.001). However, in the multivariate analysis, none of the 
factors had a significant potential effect on the diagnostic accuracy of the anti-HCV antibody detection assays.
Meta-analysis of HCV-RNA detection in DBs samples. A total of 12 HCV-RNA detection assays from 
10 different studies were analyzed: 9 PCR assays9,24,39,45–49 and 3 TMA assays27,38,48. Deek’s funnel plot asymmetry 
test revealed publication bias (P = 0.009) (SF 9).
Pooled diagnostic accuracy measures are shown in Fig. 4. Sensitivity was 97.8% (95%CI = 96.8%; 98.5%), 
specificity 99.2% (95%CI = 98.3%; 99.7%), PLR 44.8 (95%CI = 20.1; 100.2), NLR 0.04 (95%CI = 0.02; 0.06), DOR 
1966.9 (95%CI = 841.7; 4596.0), and SROC 0.996 ± 0.013, indicating high diagnostic accuracy. Sensitivity and 
specificity showed I2 > 50% (P < 0.05), suggesting considerable heterogeneity, whereas the other statistical meas-
ures had I2 < 50%. No individual study showed a significant influence on pooled estimates in the sensitivity analy-
ses. The likelihood scatter-plot (Fig. 3A2) also showed that most of the studies were in the LUQ. Thus, HCV-RNA 
detection tests in DBS samples are also useful for confirmation and exclusion of HCV infection. The theoretical 
values of PPV and NPV were calculated using the pooled PLR (44.82) and NLR (0.03) values and plotted against 
increasing HCV-RNA prevalence values (Fig. 3B2, full description in SF 4). We found a PPV of 70.2% for a 5% 
prevalence and 83.3% for a 10% prevalence, whereas NPV continued with values above 95% when prevalence 
reached 60%.
We also performed an analysis according to the type of HCV-RNA detection assay: PCR (SF 10) and TMA 
(SF 11). Pooled diagnostic accuracy measures were similar between PCR and TMA, and in turn similar to 
global estimates for HCV-RNA detection (Fig. 4). For PCR, PPV was 72.3% for a 5% prevalence and 84.7% for 













2012 Bennett et al.46 1a, 2b, 3a, 4a, 5, 6a No
United 
Kingdom — —
TaqMan real-time PCR (In-house 
2-step RT and PCR)
Real-time RT-PCR: m2000 rt (Abbott 
Molecular) 80 57 100 95.8
2010 De Crignis et al.47
1a, 1b, 
2a, 3a Yes Italy — —
SYBR Green real-time RT-PCR for 
HCV and HIV detection
Real-time RT-PCR: VERSANT HCV 
RNA 3.0 b-DNA Assay (Siemens) 25 16 93.8 100
2014 Dokubo et al.27 — No USA  < 30 — dHCV TMA (Novartis Vaccines and Diagnostics)
TMA: Procleix Ultrio Assay (Novartis 
Vaccines and Diagnostics) s 132 48 89.6 100
2016 Mössner et al.38 — Yes Denmark — — TMA: Procleix Ultrio Elite assay (Novartis Vaccines and Diagnostics)
TMA: Procleix Ultrio Elite Assay 
(Novartis Vaccines and Diagnostics) 107 85 95.3 95.5
2013 Ross et al.39 — No Germany — — TMA: VERSANT HCV RNA Qualitative Assay (Siemens)
TMA: VERSANT HCV RNA 
Qualitative Assay (Siemens) 150 100 100 100
2018 Saludes et al.45 1, 2, 3, 4 No Spain — — QuantiFast Pathogen RT-PCR + IC Kit (QIAGEN)
Abbott RealTime HCV (Abbott 
Molecular) 82 38 100 100
2012 Santos et al.44 No Brazil — — In-house qPCR In-house qPCR 168 101 98 94.3
2002 Solmone et al.48 1b, 2a, 2c, 3a, 4c, 4d No Italy — — In-house 2-step RT and PCR
Amplicor HCV Monitor (Roche 
Molecular) TMA: VERSANT HCV 
RNA Qualitative Assay (Siemens)
55 34 100 100
2002 Solmone et al.48 1b, 2a, 2c, 3a, 4c, 4d No Italy — — TMA Unspedified.
Amplicor HCV Monitor (Roche 
Molecular) TMA: VERSANT HCV 
RNA Qualitative Assay (Siemens)
55 34 100 100
2016 Soulier et al.9 1, 2, 3, 4, 5a, 6 No France 54 55,2
Real-time RT-PCR: Cobas 
Ampliprep/Cobas TaqMan HCV 
version 2 (Roche Molecular)
Real-time RT-PCR: Cobas Ampliprep/
Cobas TaqMan HCV version 2 (Roche 
Molecular)
511 315 97.1 100
2016 Soulier et al.9 1, 2, 3, 4, 5a, 6 No France 54 55,2
Real-time RT-PCR: m2000rt 
(Abbott Molecular)
Real-time RT-PCR: m2000rt (Abbott 
Molecular) 511 314 98.1 100
2018 Vázquez-Morón et al.24
1a, 1b, 2, 
3, 4, 5 Yes Spain 44.3 66.9
Quantitec SYBR Green RT-PCR 
One Step kit (Qiagen) VERSANT HCV RNA 1.0 Assay 139 108 99.1 100
Table 2. Characteristics of Studies Included in the Meta-Analysis With Respect to HCV-RNA Detection. 
Abbreviations: dHCV TMA, discriminatory HCV transcription-mediated amplification assay; GT, genotype; 
HCV, hepatitis C virus; HIV, human immunodeficiency virus; PCR, polymerase chain reaction; RT, reverse 
transcription; Se, sensitivity; Sp, specificity; TMA, transcription-mediated amplification.
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a 10% prevalence; for TMA, PPV was 68.1% for a 5% prevalence and 81.9% for a 10% prevalence, whereas NPV 
was > 90% for PCR and TMA when prevalence reached 60% (SF 4).
Meta-regression results are shown in SF 12. We found no significant values in the univariate or the mul-
tivariate analysis. Therefore, no factors showed a significant potential effect on the diagnostic accuracy of the 
HCV-RNA detection assays.
Figure 2. Anti-HCV antibody assays. Forest plot of sensitivity (A), specificity (B), positive LR (C), negative 
LR (D), diagnostic odds ratio (E), and SROC plot (F). Abbreviations: LR, likelihood ratio; SROC, summary of 
receiver operating characteristic; HCV, hepatitis C virus.
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Discussion
In this meta-analysis, we found that the internal validity of HCV screening tests in DBS samples was very high: 
pooled sensitivity values were > 96% and specificity values were > 99%. The diagnostic performance of anti-HCV 
antibody tests (ELISA, RDT, and CLA) was slightly lower than that of HCV-RNA tests (PCR and TMA), with the 
latter having higher sensitivity values. However, SROC values were > 0.985 in all of the tests analyzed.
Likelihood ratios summarize the ability of a test to predict the probability of disease. The positive value con-
firms the reliability of a positive test, whereas the negative value calls a normal result into question. Additionally, 
the characteristics of diagnostic tests (relating to the detection or exclusion of the condition of interest) may 
be described in terms of likelihood scatter-plots and the threshold values used to recommend a test for clini-
cal use, namely, 0.1 for NLR and 10.0 for PLR50. In our study, most of studies were in the LUQ (NLR < 0.1 and 
PLR > 10.0), indicating that HCV screening tests in DBS samples may be useful for either confirmation or exclu-
sion of exposure to HCV and active infection.
We also evaluated theoretical values of PPV and NPV, which were calculated to evaluate the external validity 
of HCV screening, against the increasing prevalence of HCV (see SF 3). We found similar NPV values owing 
to the high specificity of both approaches. It should be noted that NPV values were > 99% for an HCV preva-
lence < 10% and did not undergo a marked decline at higher prevalence values (NPV > 90% at 60% HCV prev-
alence), thus indicating that HCV screening could be used in DBS samples owing to the low number of false 
negatives it produces. However, PPV values were not uniform in all the techniques. The PPV for anti-HCV anti-
body tests was higher than for HCV-RNA tests, particularly when the prevalence of HCV was lower than 10%. 
Furthermore, RDT and CLA assays showed higher PPV values than ELISA assays, whereas in HCV-RNA assays, 
PCR showed higher PPV values than TMA assays when prevalence was < 10%. When we evaluated the possi-
ble use of these tests with an HCV prevalence < 5%, we found PPV values < 90% for anti-HCV antibody tests 
(except CLA) and < 85% for HCV-RNA, both of which are highly undesirable for diagnostic assays in the general 
population of most countries (HCV prevalence < 2.5%)51. In contrast, at an HCV prevalence > 10%, the PPV 
Figure 3. The likelihood scatter-plot (A1 & A2) and theoretical values of positive predicted value (PPV) and 
negative predicted value (NPV) against increasing anti-HCV antibody prevalence values (B1) and HCV-RNA 
prevalence (B2). Abbreviations: HCV, hepatitis C virus; RNA, ribonucleic acid; LUQ, left upper quadrant; RUQ, 
right upper quadrant; LUQ, left lower quadrant; LUQ, right lower quadrant.
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was for anti-HCV antibody tests > 90%, which is within acceptable limits for HCV screening in DBS samples 
and could be used in high-prevalence populations, such as PWID, prisoners or ex-prisoners, sex workers, and 
MSM3. In these key populations, screening for and treatment of hepatitis C and other interventions that reduce 
HCV transmission seem to be cost-effective52–55. In addition, use of DBS may increase uptake of HCV testing19, 
thus enabling scale-up of HCV treatment and other interventions to minimize HCV transmission54,55. However, 
further research on the cost-effectiveness of HCV screening in DBS samples in at-risk populations is needed 
before its use can be generalized. Additionally, it would be applicable to the general population in countries with 
a high prevalence of HCV, such as Egypt (14.7%), Cameroon (13.8%), Burundi (11.3%), and Uzbekistan (11.3%), 
where significant iatrogenic transmission has been reported51. Therefore, HCV screening in DBS samples with 
anti-HCV antibody tests may be an ideal diagnostic assay in endemic areas with a higher HCV prevalence, espe-
cially in populations where there is limited access to health services, laboratory facilities, or rapid diagnostic tests. 
However, HCV-RNA tests showed PPV values < 90%, particularly TMA assays (with 81.9% when prevalence was 
10%), which would not be appropriate for HCV screening as a single laboratory test. However, it should improve 
when using the reference two-step HCV screening algorithm based on serological screening followed by molecu-
lar confirmation of serology positives. Thus, HCV-RNA tests should be used with some reservations, depending 
on the technique applied and the expected HCV prevalence.
The accuracy of a systematic review depends on the quality of the studies included. The quality of the articles 
included in the present meta-analysis was moderate, since many items regarding the risk of bias were lacking or 
unclear. Some of the main drawbacks were that most of the studies were cross-sectional studies, whose design 
resembled that of case-control studies, thus providing little information about the reference standard and index 
test and unclear data on flow and timing information. Moreover, a high percentage of DBS samples were not 
collected at the point of care under real-world conditions. Therefore, the number of high-quality articles was 
moderate, and an analysis based only on high-quality studies (ie, with a low risk of bias) could not be performed.
In this meta-analysis, we evaluated the heterogeneity by the tests of Cochran’s Q and I². However, Cochran’s Q 
test is known to be poor at detecting true heterogeneity among studies, particularly when meta-analyses include 
small numbers of studies; whereas this test may have excessive power when there are many studies, particularly 
when those studies are large56. Moreover, I² test is a preferable measurement to evaluate the heterogeneity because 
Figure 4. HCV-RNA detection assays. Forest plot of sensitivity (A), specificity (B), positive LR (C), negative 
LR (D), diagnostic odds ratio (E), and SROC plot (F). Abbreviations: LR, likelihood ratio; SROC, summary of 
receiver operating characteristic; HCV, hepatitis C virus; RNA, ribonucleic acid.
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it is easy to calculate, has values between 0 and 100 (intuitive interpretation), focuses attention on the effect of 
any heterogeneity on the meta-analysis, is independent of the number of studies included in the meta-analysis 
and the type of outcome data56. In our study, we found significant heterogeneity among the studies, which is a 
common and expected characteristic in a meta-analysis of diagnostic tests. To our knowledge, there is no real 
consensus on how to interpret the heterogeneity measures in meta-analysis. In the opinion of many researchers, 
this depends on the type of meta-analysis. When performing a meta-analysis of clinical trials that evaluate the 
effects of a treatment and that included studies for estimating the same outcome, the heterogeneity should be low. 
However, the situation is different when pooling results from epidemiological studies. In our case, we performed 
a meta-analysis of epidemiological studies that had different designs and objectives, and which measured also 
different outcomes. In this type of meta-analysis, there is no way to control all possible confounding factors, so 
substantial heterogeneity between the studies can be expected. In this situation, a random effects analysis should 
be performed on the assumption that the different studies measures different things23. This heterogeneity may 
have been due to a large series of factors that could have influenced our results, such as sample size, reference 
tests, screening tests, HCV prevalence, HCV viral load, HCV genotype, HIV coinfection, DBS elution method, 
RNA extraction method, HCV-RNA amplification technique, type of PCR used, and the region of the amplified 
HCV genome. Some of these factors were analyzed, although others were not owing to the lack of data in the arti-
cles included. We analyzed whether heterogeneity was due to differences between the types of tests used in each 
study. All pooled measures for anti-HCV antibody assays showed high heterogeneity. A subgroup analysis was 
then performed according to the technique used (ELISA, TDR, or CLA) to investigate potential sources of het-
erogeneity. Thus, the HCV screening test used seemed to be responsible for part of the heterogeneity, since RDT 
and CLA became homogeneous once the analysis was stratified by the type of test. However, heterogeneity was 
maintained in the ELISA group, probably because of the high variability in the ELISA tests used by the authors. 
Furthermore, HCV-RNA tests were less heterogeneous, and when the HCV-RNA techniques (PCR or TMA) were 
analyzed separately, we found higher heterogeneity in TMA than in PCR. On the other hand, a meta-regression 
analysis found that several factors had no influence on the diagnostic accuracy of HCV screening. No individual 
study showed significant influence on pooled estimates when sensitivity analyses were performed, thus indicating 
the reliability and stability of our results.
Generalizability of HCV screening in DBS samples remains limited in specific circumstances. On the one 
hand, no uniform protocols were applied in most of studies included in our meta-analysis. For example, the HCV 
screening kits were generally from different companies, and when they were from the same company, they could 
have been subject to changes in the manufacturing process over the years. Manufacturers should formally validate 
their DBS assays for use with their commercial assays. Also important is the optimal pre-analytical treatment of 
DBS samples in relation to storage conditions (eg, temperature, humidity) and sample elution. Manufacturers 
should establish protocols for optimal pre-analytical treatment of DBS specimens. Further studies are needed 
to demonstrate the stability of DBS under different conditions. In our meta-analysis, a significant percentage of 
studies (35%) did not report information about storage conditions, with the result that sample storage conditions 
were not included in the meta-regression. In addition, the specifications of the storage conditions were very dif-
ferent, thus making it difficult to create a variable that can be entered into the meta-analysis. When the articles 
included this information, the storage conditions were very far from real-world conditions in LMICs, because 
most studies were from high-income countries. Future studies on diagnostic accuracy should assess the impact of 
environmental conditions common to low-resource field settings.
The intrinsic validity of a diagnostic test is obtained by calculating the values of sensitivity and specificity. 
Therefore, the diagnostic tests analyzed in this meta-analysis were quite valid, since the sensitivity was > 96% and 
specificity was > 99%. Only a small margin of improvement remains to raise the sensitivity to 99–100%, which 
could be achieved with assays and methodologies more appropriate for the use of DBS in the HCV screening. 
Moreover, predictive values provide relevant information when making a clinical decision about a specific test 
result, but it has the limitation that they depend on the prevalence of the disease to be diagnosed in the study 
population. Thus, the low prevalence of HCV infection ( < 5%) affects the external validity of the tests since affects 
the positive and negative predictive values.
In two recent meta-analyses, Lange et al.15,16 evaluated the diagnostic accuracy of HCV screening according 
to the type of laboratory methodology. However, in our opinion, our meta-analysis has a series of merits that 
provide a differential added value. In contrast to Lange et al., we showed pooled diagnostic accuracy measures 
(sensitivity, specificity, PPV, NPV, PLR, NLR, DOR, and SROC) according to the type of laboratory assay used 
for HCV screening (anti-HCV antibody assays [ELISA, TDR, and CLA] and HCV-RNA tests [PCR and TMA]) 
in the same meta-analysis. We showed both the internal validity and the external validity (PPV and NPV against 
the increasing prevalence of HCV) of the techniques used. We also analyzed publication bias and the impact of 
covariables on effect size using regression-based techniques.
Finally, in order to ensure that our results were interpreted appropriately, a series of points had to be taken 
into account. Firstly, this meta-analysis revealed a publication bias, indicating that there was a higher tendency 
to publish studies with favorable results than studies with unfavorable results. Secondly, the number of studies 
in some subgroup analyses was small, thus potentially leading to weak results. Thirdly, the fact that most of the 
studies included were conducted in Western countries and South America does not prevent DBS samples from 
being used in other parts of the world (eg, Asia), provided similar technology and protocols are applied. Fourthly, 
we have not done a study of cost-effectiveness, which is an important consideration in most public health inter-
ventions, especially in LMICs.
In the current era of direct-acting antivirals for HCV treatment, there is a growing need for rapid, sensi-
tive, and specific identification of HCV-infected individuals to enable effective prompt HCV therapy, implement 
HCV-specific infection control measures, and decrease HCV prevalence. HCV screening tests in DBS samples 
may have the potential to meet some of these needs, although their current limitations in diagnostic performance 
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should be considered. More sensitive assays must be developed to increase the potential of DBS as an HCV 
screening tool.
Conclusions
In conclusion, HCV screening from DBS samples has an outstanding diagnostic performance, with no relevant 
differences in diagnostic accuracy according to the type of technique used for detection of anti-HCV antibodies 
or HCV-RNA. However, external validity may be limited when the prevalence of HCV is low. This approach 
could be useful for the implementation of national programs for the control of HCV infections in LMICs and 
in difficult-to-access populations. Further studies to determine diagnostic accuracy in real-world settings are 
needed.
Data Availability
All relevant data are within the paper and its Supporting Information files.
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